Does Rallies track congressional trades in IDXX?

Yes. Rallies tracks politician and congressional stock disclosures for IDXX, including reported purchases, sales, dates, owners, and trade amounts when available.

Is IDXX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IDXX. It does not provide personalized investment advice.

IDXX (IDEXX Laboratories) Stock Analysis - Politician Trades

IDEXX Laboratories (IDXX) is a publicly traded Healthcare sector company. As of May 20, 2026, IDXX trades at $551.48 with a market cap of $43.05B and a P/E ratio of 40.37. IDXX moved +1.27% today. Year to date, IDXX is -18.86%; over the trailing twelve months it is +7.04%. Its 52-week range spans $356.14 to $769.98. Analyst consensus is buy with an average price target of $693.17. Rallies surfaces IDXX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded IDXX stock?

Recent politician trading activity in IDXX includes disclosures from April Delaney, April Delaney, April Delaney, April Delaney, and Byron Donalds. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.

IDXX Key Metrics

Key financial metrics for IDXX
Metric	Value
Price	$551.48
Market Cap	$43.05B
P/E Ratio	40.37
EPS	$13.69
Dividend Yield	0.00%
52-Week High	$769.98
52-Week Low	$356.14
Volume	435.42K
Avg Volume	0
Revenue (TTM)	$4.45B
Net Income	$1.10B
Gross Margin	62.05%

Congressional Trades in IDXX

April Delaney sale IDXX on Jan 13, 2026 (amount: $15.00K).
April Delaney sale IDXX on Dec 2, 2025 (amount: $15.00K).
April Delaney sale IDXX on Oct 29, 2025 (amount: $15.00K).
April Delaney sale IDXX on Oct 16, 2025 (amount: $15.00K).
Byron Donalds purchase IDXX on Sep 4, 2025 (amount: $15.00K) for Spouse.

Latest IDXX News

IDEXX jumps after Q1 beat and higher 2026 EPS outlook to $14.45–$14.90 — May 6, 2026
IDEXX Laboratories Beats Quarterly EPS and Revenue Estimates with 15% Pet Segment Growth — May 5, 2026
IDEXX jumps after Q1 beat and raised 2026 revenue, EPS outlook — May 5, 2026
Idexx Laboratories Posts $278.4M Q1 Profit, Boosts Annual Revenue Outlook to $4.68B–$4.76B — May 5, 2026
IDEXX slides 3.5% as traders de-risk ahead of May 5 earnings — Apr 29, 2026

Recent IDXX Insider Trades

Hunt Nimrata sold 1.76K (~$1.12M) on Mar 3, 2026.
MAZELSKY JONATHAN JAY sold 1.28K (~$833.51K) on Feb 26, 2026.
MAZELSKY JONATHAN JAY sold 1.09K (~$713.38K) on Feb 26, 2026.

IDXX Analyst Consensus

7 analysts cover IDXX: 0 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $693.17.

Common questions about IDXX

Which politicians traded IDXX stock?: Recent politician trading activity in IDXX includes disclosures from April Delaney, April Delaney, April Delaney, April Delaney, and Byron Donalds. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in IDXX?: Yes. Rallies tracks politician and congressional stock disclosures for IDXX, including reported purchases, sales, dates, owners, and trade amounts when available.
Is IDXX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IDXX. It does not provide personalized investment advice.